Bridgebio Q4 2022 Earnings Report
Key Takeaways
BridgeBio Pharma reported its Q4 and full year 2022 financial results. The company ended the quarter with $466.2 million in cash, cash equivalents, marketable securities, and restricted cash, providing runway into 2024. Key programs like Acoramidis, low-dose infigratinib and Encaleret continue to progress through clinical trials.
Phase 3 ATTRibute-CM trial of acoramidis continues with topline data expected in mid-2023.
Phase 2 PROPEL 2 trial of low-dose infigratinib progresses with Cohort 5 data expected in March 2023.
Phase 3 CALIBRATE trial of encaleret initiated with topline data expected in late 2023 or the first half of 2024.
Ended quarter with $466.2 million in cash, cash equivalents, marketable securities, and restricted cash (current), providing runway into 2024.
Bridgebio
Bridgebio
Forward Guidance
BridgeBio anticipates important upcoming readouts from its achondroplasia Phase 2 trial in March, and its ATTR-CM Phase 3 trial mid-year. The company expects to continue to allocate capital carefully to preserve runway and optionality and will continue to look for ways to extend runway by considering potential royalty monetizations and partnerships.